For the CRSwNP indication, the BLA includes data from the ANCHOR-1 (ClinicalTrials.gov Identifier: NCT05274750) and ANCHOR-2 (ClinicalTrials.gov Identifier: NCT05281523) trials, which enrolled ...
Hosted on MSN2mon
China’s NMPA approves GSK’s Nucala for CRSwNP treatmentThe China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback